{"id":105990,"date":"2018-10-24T22:50:04","date_gmt":"2018-10-24T22:50:04","guid":{"rendered":"http:\/\/news.alabamanewsreporter.com\/story\/105990\/viral-clearance-market-worth-7245-million-by-2023-says-marketandmarkets.html"},"modified":"2018-10-24T22:50:04","modified_gmt":"2018-10-24T22:50:04","slug":"viral-clearance-market-worth-7245-million-by-2023-says-marketandmarkets","status":"publish","type":"post","link":"https:\/\/www.alaskanewsdesk.com\/news\/story\/105990\/viral-clearance-market-worth-7245-million-by-2023-says-marketandmarkets.html","title":{"rendered":"Viral Clearance Market Worth $724.5 Million by 2023 Says Marketandmarkets"},"content":{"rendered":"
\"\"<\/a><\/p>\n
\n
The key players in the global viral clearance market are Wuxi Biologics (Cayman) (China), Merck KGaA (Germany), Charles River Laboratories International Inc. (US), and Texcell Inc. (France), Kedrion (Italy), Vironova Biosafety (Sweden), Clean Cells (France), BSL BIOSERVICE Scientific Laboratories Munich GmbH (Germany), and ViruSure GmbH (Austria).<\/div>\n<\/div>\n<\/div>\n
According to the new market research report “Viral Clearance Market by Application (Recombinant Proteins, Blood, Vaccines), End User (Pharmaceutical & Biotechnology Companies, CROs), Method (Viral Removal (Chromatography, Nanofiltration), Viral Inactivation (Low pH)) – Global Forecasts to 2023” published by MarketsandMarkets\u2122, The global viral clearance market is expected to reach USD 724.5 million by 2023 from USD 271.2 million in 2018, at a CAGR of 21.7% during the forecast period.<\/div>\n

The key factors driving the growth of this market include growth in the pharmaceutical and biotechnology industries, increasing number of new drug launches, R&D investments in life science, advancements in nanofiltration technology, and the high incidence and large economic burden of chronic diseases.<\/p>\n

Speak to our analyst and gain crucial industry insights that will help your business grow:<\/strong><\/p>\n

https:\/\/www.marketsandmarkets.com\/speaktoanalyst.asp?id=62681197<\/a> <\/strong><\/p>\n

By application, the recombinant proteins segment is expected to account for the largest share of the market in 2018<\/strong><\/p>\n

On the basis of application, the global market is segmented into four categories recombinant proteins, blood and blood products, vaccines, and other applications. In 2018, the recombinant proteins segment is expected to account for the largest share of the viral clearance market owing to the high potential of recombinant proteins to treat various diseases, fewer side effects, and shorter development time as compared to small molecules. Furthermore, the regulatory requirement to demonstrate the capacity of the purification process to effectively clear infectious viruses during the manufacturing of recombinant proteins is also expected to support the growth of this market segment during the forecast period.<\/p>\n

Browse and in-depth TOC on ” Viral Clearance Market ” <\/strong><\/p>\n

118 – Tables<\/strong><\/p>\n

33 – Figures <\/strong><\/p>\n

159 – Pages <\/strong><\/p>\n

By end user, the pharmaceutical & biotechnology companies segment is expected to account for the largest share of the market in 2018<\/strong><\/p>\n

By end user, the viral clearance market is segmented into pharmaceutical & biotechnology companies, CROs, academic research institutes, and other end users. In 2018, the pharmaceutical & biotechnology companies segment is expected to account for the largest share of the global market. The large share of this segment can be attributed to the rapid expansion of the biopharmaceutical industry, growth in the number of research activities in life sciences, increasing R&D investments in drug development, and increasing number of drug launches.<\/p>\n

View more detailed TOC @ <\/strong><\/p>\n

https:\/\/www.marketsandmarkets.com\/Market-Reports\/viral-clearance-market-62681197.html<\/a><\/strong><\/p>\n

By method, the viral removal segment is expected to account for the largest share of the market in 2018<\/strong><\/p>\n

On the basis of method, the viral clearance market is segmented into viral removal and viral inactivation. In 2018, the viral removal segment is expected to account for the largest share of the global market due to the growth in biopharmaceutical R&D activities; the high acceptance of this method; and the accuracy, speed, and flexibility provided by the method in life sciences research.<\/p>\n

Request for Free Sample Report @ <\/strong><\/p>\n

https:\/\/www.marketsandmarkets.com\/pdfdownload.asp?id=62681197<\/a><\/strong><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> MarketsandMarkets<\/a>
Contact Person:<\/strong> Mr. Shelly Singh
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 1-888-600-6441
Address:<\/strong>630 Dundee Road Suite 430
City:<\/strong> Northbrook
State:<\/strong> IL
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.marketsandmarkets.com\/Market-Reports\/viral-clearance-market-62681197.html<\/a><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

The key players in the global viral clearance market are Wuxi Biologics (Cayman) (China), Merck KGaA (Germany), Charles River Laboratories International Inc. (US), and Texcell Inc. (France), Kedrion (Italy), Vironova<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/www.alaskanewsdesk.com\/news\/wp-json\/wp\/v2\/posts\/105990"}],"collection":[{"href":"https:\/\/www.alaskanewsdesk.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.alaskanewsdesk.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.alaskanewsdesk.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.alaskanewsdesk.com\/news\/wp-json\/wp\/v2\/comments?post=105990"}],"version-history":[{"count":0,"href":"https:\/\/www.alaskanewsdesk.com\/news\/wp-json\/wp\/v2\/posts\/105990\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.alaskanewsdesk.com\/news\/wp-json\/wp\/v2\/media?parent=105990"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.alaskanewsdesk.com\/news\/wp-json\/wp\/v2\/categories?post=105990"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.alaskanewsdesk.com\/news\/wp-json\/wp\/v2\/tags?post=105990"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}